Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer

Breast Cancer Research and Treatment

Volumn 125, Issue 3, 2011, Pages 637-646

  Schmidt, Marcus ^a   Petry, Ilka Brigitte ^a   Böhm, Daniel ^a   Lebrecht, Antje ^a   Von Törne, Christian ^b   Gebhard, Susanne ^a   Gerhold Ay, Aslihan ^a   Cotarelo, Cristina ^a   Battista, Marco ^a   Schormann, Wiebke ^c   Freis, Evgenia ^c   Selinski, Silvia ^c   Ickstadt, Katja ^c   Rahnenführer, Jörg ^c   Sebastian, Martin ^a   Schuler, Martin ^d   Koelbl, Heinz ^a   Gehrmann, Mathias ^b   Hengstler, Jan G ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b SIEMENS AG   (Germany)

^c TU DORTMUND UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Breast cancer; EpCAM; Gene expression; Node negative; Prognosis; Proliferation

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; RNA;

ADULT; ARTICLE; BREAST CANCER; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; METASTASIS; MICROARRAY ANALYSIS; NODE NEGATIVE BREAST CANCER; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL PROLIFERATION; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; RNA;

EID: 79151486669     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0856-5     Document Type: Article

References (30)

1. SV Litvinov MP Velders HA Bakker, et al. 1994 Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule J Cell Biol 125 437 446 1:CAS:528:DyaK2cXisVWhurs%3D 10.1083/jcb.125.2.437 8163559
2. S Naundorf S Preithner P Mayer, et al. 2002 In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment Int J Cancer 100 101 110 1:CAS:528:DC%2BD38XksVGntbc%3D 10.1002/ijc.10443 12115595 (Pubitemid 34602073)
3. N Prang S Preithner K Brischwein, et al. 2005 Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines Br J Cancer 92 342 349 1:CAS:528: DC%2BD2MXhtFWhu7k%3D 15655555
4. M Amann K Brischwein P Lutterbuese, et al. 2008 Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3 Cancer Res 68 143 151 1:CAS:528:DC%2BD1cXos12m 10.1158/0008-5472.CAN-07- 2182 18172306 (Pubitemid 351380115)
5. M Sebastian P Kiewe W Schuette, et al. 2009 Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study J Immunother 32 195 202 1:CAS:528:DC%2BD1MXit1Cisr4%3D 10.1097/CJI.0b013e318195b5bb 19238019
6. M Schmidt ME Scheulen C Dittrich, et al. 2010 An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer Ann Oncol 21 275 282 1:STN:280:DC%2BC3c%2Fls1entA%3D%3D 10.1093/annonc/mdp314 19633042
7. G Gastl G Spizzo P Obrist, et al. 2000 Ep-CAM overexpression in breast cancer as a predictor of survival Lancet 356 1981 1982 1:CAS:528: DC%2BD3MXitlagug%3D%3D 10.1016/S0140-6736(00)03312-2 11130529
8. G Spizzo P Went S Dirnhofer, et al. 2004 High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer Breast Cancer Res Treat 86 207 213 1:CAS:528:DC%2BD2cXmt1Kqt74%3D 10.1023/B:BREA.0000036787.59816. 01 15567937 (Pubitemid 39070963)
9. JG Hengstler EO Bockamp M Hermes, et al. 2006 Oncogene-blocking therapies: new insights from conditional mouse tumor models Curr Cancer Drug Targets 6 603 612 1:CAS:528:DC%2BD28XhtFSju7%2FE 10.2174/156800906778742488 17100566 (Pubitemid 44691002)
10. M Schmidt D Hasenclever M Schaeffer, et al. 2008 Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer Clin Cancer Res 14 5849 5855 1:CAS:528:DC%2BD1cXhtFaitrjM 10.1158/1078-0432.CCR-08-0669 18794096
11. Y Wang JGM Klijn Y Zhang, et al. 2005 Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer Lancet 365 671 679 1:CAS:528:DC%2BD2MXhsVOitLk%3D 15721472
12. C Desmedt F Piette S Loi, et al. 2007 Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series Clin Cancer Res 13 3207 3214 1:CAS:528:DC%2BD2sXmtVajur0%3D 10.1158/1078-0432.CCR-06-2765 17545524 (Pubitemid 46944903)
13. S Loi B Haibe-Kains C Desmedt, et al. 2007 Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade J Clin Oncol 25 1239 1246 1:CAS:528:DC%2BD2sXkvFyms7w%3D 10.1200/JCO.2006.07.1522 17401012 (Pubitemid 46640570)
14. M Schmidt D Böhm C von Törne, et al. 2008 The humoral immune system has a key prognostic impact in node-negative breast cancer Cancer Res 68 5405 5413 1:CAS:528:DC%2BD1cXnvFyjtb4%3D 10.1158/0008-5472.CAN-07-5206 18593943
15. LM McShane DG Altman W Sauerbrei, et al. 2005 Reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 9067 9072 10.1200/JCO.2004.01.0454 16172462
16. JG Hengstler J Lange A Kett, et al. 1999 Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer Cancer Res 59 3206 3214 1:CAS:528:DyaK1MXksVCqu74%3D 10397267
17. M Smid Y Wang Y Zhang, et al. 2008 Subtypes of breast cancer show preferential site of relapse Cancer Res 68 3108 3114 1:CAS:528: DC%2BD1cXltlSmt7Y%3D 10.1158/0008-5472.CAN-07-5644 18451135
18. M Schmidt JG Hengstler C von Törne, et al. 2009 Coordinates in the universe of node-negative breast cancer revisited Cancer Res 69 2695 2698 1:CAS:528:DC%2BD1MXjvVWju74%3D 10.1158/0008-5472.CAN-08-4013 19318558
19. AM Sieuwerts J Kraan J Bolt, et al. 2009 Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells J Natl Cancer Inst 101 61 66 1:CAS:528:DC%2BD1MXltFSltQ%3D%3D 19116383
20. B Tanner D Hasenclever K Stern, et al. 2006 ErbB-3 predicts survival in ovarian cancer J Clin Oncol 24 4317 4323 1:CAS:528:DC%2BD28XhtVGju7nI 10.1200/JCO.2005.04.8397 16896008 (Pubitemid 46630790)
21. M Trzpis PMJ McLaughlin LMFH de Leij, et al. 2007 Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule Am J Pathol 171 386 395 1:CAS:528:DC%2BD2sXpsFaitLg%3D 10.2353/ajpath.2007.070152 17600130 (Pubitemid 47344671)
22. WA Osta Y Chen K Mikhitarian, et al. 2004 EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy Cancer Res 64 5818 5824 1:CAS:528:DC%2BD2cXmslaks74%3D 10.1158/0008-5472.CAN-04-0754 15313925 (Pubitemid 39095582)
23. DS Oh MA Troester J Usary, et al. 2006 Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers J Clin Oncol 24 1656 1664 1:CAS:528:DC%2BD28XksVKgtL0%3D 10.1200/JCO.2005.03.2755 16505416 (Pubitemid 46622136)
24. H Dai L van't Veer J Lamb, et al. 2005 A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients Cancer Res 65 4059 4066 1:CAS:528:DC%2BD2MXktlSmsLc%3D 10.1158/0008-5472.CAN-04- 3953 15899795 (Pubitemid 40775642)
25. C Sotiriou P Wirapati S Loi, et al. 2006 Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis J Natl Cancer Inst 98 262 272 1:CAS:528:DC%2BD28Xhs1Skt74%3D 10.1093/jnci/djj052 16478745 (Pubitemid 43264710)
26. C Fan D Oh L Wessels, et al. 2006 Concordance among gene-expression-based predictors for breast cancer N Engl J Med 355 560 569 1:CAS:528: DC%2BD28XotVKnur4%3D 10.1056/NEJMoa052933 16899776 (Pubitemid 44200649)
27. M Münz R Zeidler O Gires 2005 The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP Cancer Lett 225 151 157 10.1016/j.canlet.2004.11.048 15922867 (Pubitemid 40732778)
28. T Nübel J Preobraschenski H Tuncay, et al. 2009 Claudin-7 regulates EpCAM-mediated functions in tumor progression Mol Cancer Res 7 285 299 10.1158/1541-7786.MCR-08-0200 19276185
29. A Ziegler R Heidenreich H Braumüller, et al. 2009 EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion Blood 113 3494 3502 1:CAS:528:DC%2BD1MXkslCku70%3D 10.1182/blood-2008-08-175109 19188665
30. D-S Schmidt P Klingbeil M Schnölzer, et al. 2004 CD44 variant isoforms associate with tetraspanins and EpCAM Exp Cell Res 297 329 347 1:CAS:528:DC%2BD2cXltVOisL8%3D 10.1016/j.yexcr.2004.02.023 15212938 (Pubitemid 38798397)